Literature DB >> 15203151

Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.

Tianbao Lu1, Thomas Markotan, Frank Coppo, Bruce Tomczuk, Carl Crysler, Stephen Eisennagel, John Spurlino, Lisa Gremminger, Richard M Soll, Edward C Giardino, Roger Bone.   

Abstract

Through structure-based drug design and parallel synthesis, we have discovered a novel series of nonpeptidic phenyl-based thrombin inhibitors using oxyguanidines as guanidine bioisosteres. These compounds have been found to be highly potent, highly selective, and orally bioavailable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203151     DOI: 10.1016/j.bmcl.2004.05.002

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Macrosteres: The Deltic Guanidinium Ion.

Authors:  Kenji Mishiro; Fanghao Hu; Daniel W Paley; Wei Min; Tristan H Lambert
Journal:  European J Org Chem       Date:  2016-03-14

2.  New synthetic thrombin inhibitors: molecular design and experimental verification.

Authors:  Elena I Sinauridze; Alexey N Romanov; Irina V Gribkova; Olga A Kondakova; Stepan S Surov; Aleksander S Gorbatenko; Andrey A Butylin; Mikhail Yu Monakov; Alexey A Bogolyubov; Yuryi V Kuznetsov; Vladimir B Sulimov; Fazoyl I Ataullakhanov
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

3.  Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA.

Authors:  Karel Mena-Ulecia; William Tiznado; Julio Caballero
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

4.  Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?

Authors:  David Ramírez; Julio Caballero
Journal:  Molecules       Date:  2018-04-28       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.